Multivalent bi-specific nanobioconjugate engager for targeted cancer immunotherapy

Area of Science:

• Immunology
• Nanotechnology
• Oncology

Background:

• Tumor-targeted immunotherapy aims for specific cancer cell killing with reduced toxicity.
• Current immunotherapies face challenges like low potency, poor immune memory, and limited efficacy against tumors with low target receptor levels.

Purpose of the Study:

• To develop a novel multivalent bi-specific nanobioconjugate engager (mBiNE) using nanoparticles.
• To enhance selective, immune-mediated cancer cell eradication.
• To stimulate durable anti-tumor immune responses.

Main Methods:

• A modular design approach was used to create the mBiNE.
• The mBiNE simultaneously targets human epidermal growth factor receptor 2 (HER2) on cancer cells and pro-phagocytosis signaling via calreticulin.
• HER2-targeted phagocytosis and subsequent anti-tumor immunity were analyzed.

Main Results:

• The mBiNE effectively stimulated HER2-targeted phagocytosis.
• Durable anti-tumor immune responses were generated against HER2-expressing tumors.
• Immune activation was initially receptor-dependent, but subsequent immunity protected against HER2-negative tumor cells.

Conclusions:

• The mBiNE represents a new targeted nanomaterial-immunotherapy platform.
• This platform stimulates both innate and adaptive immunity.
• It promotes a universal anti-tumor response, overcoming limitations of current therapies.